Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AbSci (ABSI)
NASDAQ:ABSI
Holding ABSI?
Track your performance easily
ABSI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.11 - $6.72
Previous Close$3.98
Volume1.24M
Average Volume (3M)1.48M
Market Cap
$451.95M
Enterprise Value$422.35M
Total Cash (Recent Filing)$42.94M
Total Debt (Recent Filing)$13.33M
Price to Earnings (P/E)―
Beta2.72
Next Earnings
Nov 06, 2024EPS Estimate
-$0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding113,556,334
10 Day Avg. Volume1,038,231
30 Day Avg. Volume1,477,734
Standard Deviation0.36
R-Squared0.10
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)2.21
Price to Sales (P/S)139.06
Price to Cash Flow (P/CF)-6.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue129.95
Enterprise Value/Gross Profit73.86
Enterprise Value/Ebitda-7.05
Forecast
1Y Price Target
$8.25Price Target Upside91.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
AbSci News
Bulls Say, Bears Say
Bulls Say
Clinical PotentialAbsci reported promising preclinical data from its first clinical candidate ABS-101, demonstrating best-in-class potential for the treatment of inflammatory bowel disease.
Financial StabilityAbsci had approximately $161.5M in cash and cash equivalents, which is believed to be sufficient to support operations into the first half of 2027.
Partnership InterestsABS-101 has generated a lot of partnership interests due to its pre-clinical data and AI-assisted, epitope-specific targeting capability.
Bears Say
EarningsQ1 revenues of $0.9M were well below the Street's expectations of $2.1M.
Financial PerformanceFor 4Q23, Absci reported technology development revenues below consensus estimates and a net loss per share greater than the consensus estimated net loss.
RevenuesFor 4Q23, the company reported technology development revenues of $0.3M, compared to the consensus estimate of $2.2M, and a net loss of $0.25 per share, compared to the consensus estimated net loss of $0.22 per share.
---
Ownership Overview
35.93% Insiders
18.57% Mutual Funds
40.65% Other Institutional Investors
4.85% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABSI FAQ
What was AbSci’s price range in the past 12 months?
AbSci lowest stock price was $1.11 and its highest was $6.72 in the past 12 months.
What is AbSci’s market cap?
Currently, no data Available
When is AbSci’s upcoming earnings report date?
AbSci’s upcoming earnings report date is Nov 06, 2024 which is in 47 days.
How were AbSci’s earnings last quarter?
AbSci released its earnings results on Aug 14, 2024. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.181 by -$0.039.
Is AbSci overvalued?
According to Wall Street analysts AbSci’s price is currently Undervalued.
Does AbSci pay dividends?
AbSci does not currently pay dividends.
What is AbSci’s EPS estimate?
AbSci’s EPS estimate is -$0.19.
How many shares outstanding does AbSci have?
AbSci has 113,556,335 shares outstanding.
What happened to AbSci’s price movement after its last earnings report?
AbSci reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.181. Following the earnings report the stock price went up 10.992%.
Which hedge fund is a major shareholder of AbSci?
Currently, no hedge funds are holding shares in ABSI
---
AbSci Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.25 (91.42% Upside)
$8.25 (91.42% Upside)
Blogger Sentiment
Bullish
ABSI Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Negative
Last 7 Days >0.1%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
155.12%
12-Months-Change
Fundamentals
Return on Equity
-42.24%
Trailing 12-Months
Asset Growth
0.54%
Trailing 12-Months
Company Description
AbSci
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
---
ABSI Earnings Call
Q2 2024
0:00 / 0:00
---
ABSI Stock 12 Month Forecast
Average Price Target
$8.25
▲(91.42% Upside)
Technical Analysis
Best Analysts Covering ABSI
1 Year
1 Year Success Rate
4/8 ratings generated profit
1 Year Average Return
+96.16%
reiterated a buy rating last month
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +96.16% per trade.
---